Meropenem And Sodium Chloride

Meropenem is a broad-spectrum carbapenem antibiotic used to treat severe bacterial infections, including meningitis and intra-abdominal infections, by inhibiting bacterial cell wall synthesis.

The standard adult dosage of meropenem depends heavily on the type and severity of the infection being treated, as well as the patient’s renal function. For most complicated intra-abdominal or skin infections, the typical dose is 500 mg every 8 hours or 1 gram every 8 hours administered intravenously. In cases of bacterial meningitis or very severe infections caused by less susceptible organisms (like Pseudomonas aeruginosa), a higher dose of 2 grams every 8 hours is often required. Clinical studies have shown that for certain resistant pathogens, extended infusions (over 3 to 4 hours) may be utilized to maximize the time the drug concentration remains above the Minimum Inhibitory Concentration (MIC) of the bacteria.

For pediatric patients 3 months of age and older, dosing is usually weight-based.

• Intra-abdominal infections: 20 mg/kg every 8 hours (maximum dose of 1 gram).
• Skin and skin structure infections: 10 mg/kg every 8 hours (maximum dose of 500 mg).
• Meningitis: 40 mg/kg every 8 hours (maximum dose of 2 grams).

For neonates and infants under 3 months of age, dosing is further adjusted based on gestational age and chronological age due to the immaturity of renal clearance mechanisms. Your pediatrician will calculate the precise dose required for your child.

Renal Impairment

Since meropenem is primarily cleared by the kidneys, dosage adjustments are mandatory for patients with a Creatinine Clearance (CrCl) of less than 50 mL/min.

• CrCl 26-50 mL/min: The standard dose is given every 12 hours.
• CrCl 10-25 mL/min: One-half of the standard dose is given every 12 hours.
• CrCl <10 mL/min: One-half of the standard dose is given every 24 hours.

Hepatic Impairment

No dosage adjustment is typically necessary for patients with liver disease, as meropenem is not significantly metabolized by the liver.

Elderly Patients

In elderly patients, healthcare providers often assess kidney function before determining the dose. While age itself does not require a dose change, the natural decline in renal function associated with aging often necessitates a lower dose or extended dosing interval.

Meropenem is administered directly into a vein (intravenously) by a nurse or doctor. It is not available in an oral form (tablet or capsule) because it is destroyed by stomach acid and poorly absorbed by the gut. If you are receiving meropenem at home through an outpatient parenteral antimicrobial therapy (OPAT) program, you must follow the sterile technique instructions provided by your home health nurse.

• Storage: The dry powder should be stored at room temperature. Once reconstituted, the solution's stability varies (usually 1-3 hours at room temperature or up to 24 hours in a refrigerator), depending on the diluent used. Always check for particles or discoloration before administration.

In a hospital setting, it is unlikely that a dose will be missed. However, if you are receiving this at home and miss a dose, contact your healthcare provider or infusion service immediately. Do not double the dose to catch up, as this can increase the risk of side effects, particularly seizures.

An overdose of meropenem is most likely to occur in patients with unrecognized renal impairment. Symptoms of an overdose may include seizures, tremors, or severe mental status changes. In the event of an overdose, the medication should be discontinued, and supportive care provided. Meropenem can be removed from the blood via hemodialysis, which may be necessary if the patient has severe kidney failure.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or stop the treatment early, even if you feel better, as this can lead to antibiotic resistance.

Most patients tolerate meropenem well, but like all powerful antibiotics, it can cause side effects. The most frequently reported adverse reactions (occurring in approximately 1% to 10% of patients) include:

• Gastrointestinal Issues: Diarrhea is the most common complaint. Patients may also experience nausea and vomiting. These symptoms are usually mild and resolve once the treatment is completed.
• Headache: A dull or throbbing sensation in the head may occur shortly after infusion.
• Local Site Reactions: Since the drug is given IV, patients often experience pain, redness, or swelling at the site of the injection (phlebitis).
• Rash: A mild, itchy skin rash may develop.

Meropenem is a high-alert medication that must be used with caution. Before starting treatment, it is vital to inform your healthcare provider of your full medical history, especially any history of allergies to other antibiotics. Because meropenem is a beta-lactam, there is a risk of cross-reactivity in patients who are allergic to penicillins or cephalosporins. While many people with a mild penicillin allergy can safely take meropenem, those with a history of anaphylaxis (a severe, life-threatening reaction) to any beta-lactam should generally avoid it.

No FDA black box warnings for Meropenem. Despite the absence of a black box warning, the drug carries significant warnings regarding its potential to lower the seizure threshold and its interaction with certain seizure medications.

• Seizure Disorders: Meropenem has been associated with CNS adverse effects, including seizures and encephalopathy. This risk is highest in patients with known brain disorders, such as strokes or tumors, and in those with impaired kidney function. If a seizure occurs during treatment, the drug is typically discontinued.

There are no drugs that are strictly "contraindicated" in a way that they can never be used under any circumstances, but there is one combination that is strongly discouraged due to extreme risk:

• Valproic Acid / Sodium Valproate: Meropenem significantly reduces the blood levels of valproic acid (a medication used for seizures and bipolar disorder). In many cases, valproic acid levels drop below the therapeutic range within 24 hours of starting meropenem, leading to a high risk of breakthrough seizures. This interaction is not easily managed by increasing the valproic acid dose; therefore, alternative antibiotics are usually recommended for patients on valproate.

• Probenecid: This medication, used for gout, inhibits the renal excretion of meropenem. This leads to a 38% increase in the area under the curve (AUC) of meropenem and extends its half-life. While not always avoided, the combination requires careful monitoring for meropenem toxicity.

Meropenem must NEVER be used in the following circumstances:

1. 1Severe Hypersensitivity to Meropenem: Patients who have had a documented anaphylactic reaction, Stevens-Johnson Syndrome, or other severe allergic reactions specifically to meropenem.
2. 2Severe Hypersensitivity to other Carbapenems: Due to the nearly identical chemical structures, there is a 100% risk of cross-reactivity among drugs in the carbapenem class (e.g., imipenem, ertapenem, doripenem).

These are conditions where the benefit of using meropenem must be carefully weighed against the risks:

Meropenem is classified as a Pregnancy Category B medication under the older FDA system. Animal studies using high doses (up to 37 times the human dose) have not shown evidence of harm to the fetus or impaired fertility. However, there are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, meropenem should be used during pregnancy only if clearly needed. It is generally reserved for severe infections where the benefit to the mother outweighs the potential risk to the developing fetus.

Meropenem is excreted in human breast milk in very small amounts. The risk to the nursing infant is considered low, but potential effects include changes in the infant’s gut flora (leading to diarrhea) or the development of an allergic sensitization. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Monitoring the infant for diarrhea or thrush is recommended.

Meropenem is FDA-approved for use in pediatric patients. It is specifically approved for children 3 months and older for the treatment of meningitis and intra-abdominal infections. In recent years, its use has been extended to neonates and infants under 3 months of age for various infections, though the dosing must be meticulously calculated based on both weight and the maturity of the kidneys. It is not approved for skin infections in pediatric patients.

Meropenem is a bactericidal agent that acts by interfering with bacterial cell wall synthesis. It has a high affinity for Penicillin-Binding Proteins (PBPs), which are essential enzymes involved in the cross-linking of the peptidoglycan layer. By binding to PBPs (specifically PBP 2 and 3 in Gram-negative bacteria), meropenem halts the construction of the cell wall, leading to rapid bacterial death. Its carbapenem structure allows it to penetrate the outer membrane of Gram-negative bacteria through specialized channels called porins (specifically the OmpD porin), making it effective against pathogens that are resistant to other beta-lactams.

The efficacy of meropenem is "time-dependent." This means that the most important factor for killing bacteria is the amount of time the concentration of the drug in the blood remains above the Minimum Inhibitory Concentration (MIC) of the target bacteria (T > MIC). For carbapenems, the goal is typically for the drug level to exceed the MIC for at least 40% of the dosing interval. This is why healthcare providers sometimes use extended infusions (e.g., over 3 hours) for difficult-to-treat infections.

| Parameter | Value |